688235 百济神州
已收盘 07-30 15:00:00
资讯
新帖
简况
港股异动 | 百奥赛图-B(02315)涨超10% 与百济神州达成抗体分子全球许可协议 机构称上半年经营情况超预期
智通财经 · 06:48
港股异动 | 百奥赛图-B(02315)涨超10% 与百济神州达成抗体分子全球许可协议 机构称上半年经营情况超预期
生物制品行业深度报告:多发性硬化 百亿美金市场 BTKI发展前景广阔
开源证券 · 07-29 16:00
生物制品行业深度报告:多发性硬化 百亿美金市场 BTKI发展前景广阔
创新药,彻底疯了
北海茶客投研笔记 · 07-29 13:31
创新药,彻底疯了
一线疗法!百济神州/安进在国内启动 DLL3/CD3 双抗新 III 期临床
Insight数据库 · 07-29 09:05
一线疗法!百济神州/安进在国内启动 DLL3/CD3 双抗新 III 期临床
港股收评:午后回升!恒指小幅下跌0.15%,创新药涨幅抢眼,三胎概念股高开低走
格隆汇 · 07-29 08:21
港股收评:午后回升!恒指小幅下跌0.15%,创新药涨幅抢眼,三胎概念股高开低走
基金二季报陆续披露,中欧葛兰等基金经理加码创新药板块
全景网 · 07-29 07:19
基金二季报陆续披露,中欧葛兰等基金经理加码创新药板块
百济神州:百泽安获欧洲药品管理局人用药品委员会积极意见
智通财经 · 07-29 02:45
百济神州:百泽安获欧洲药品管理局人用药品委员会积极意见
国内稀缺、研发实力强!7家创新药企手握重磅新药
巨丰投顾 · 07-28 21:59
国内稀缺、研发实力强!7家创新药企手握重磅新药
港股异动 | 百奥赛图-B(02315)涨超3% 近日宣布与百济神州达成抗体分子全球许可协议
智通财经 · 07-28 03:20
港股异动 | 百奥赛图-B(02315)涨超3% 近日宣布与百济神州达成抗体分子全球许可协议
单抗概念盘中拉升,誉衡药业涨停
市场透视 · 07-25
单抗概念盘中拉升,誉衡药业涨停
百济神州-U股价微跌0.19% 二季度获201家基金重仓
金融界 · 07-24
百济神州-U股价微跌0.19% 二季度获201家基金重仓
新事丨罗氏终止TIGIT全部三期临床
健识局 · 07-24
新事丨罗氏终止TIGIT全部三期临床
百济潜在 BIC 蛋白降解剂获批新临床
Insight数据库 · 07-23
百济潜在 BIC 蛋白降解剂获批新临床
单抗概念盘中拉升,百济神州-U涨0.48%
市场透视 · 07-23
单抗概念盘中拉升,百济神州-U涨0.48%
券商资管系公募,排名来了!
中国基金报 · 07-22
券商资管系公募,排名来了!
百济神州盘中异动 早盘快速上涨3.02%
市场透视 · 07-22
百济神州盘中异动 早盘快速上涨3.02%
公募基金2025年二季报全扫描【国信金工】
量化藏经阁 · 07-22
公募基金2025年二季报全扫描【国信金工】
葛兰、谢治宇最新持仓曝光:共同聚焦创新药,这些个股被重仓
每经网 · 07-21
葛兰、谢治宇最新持仓曝光:共同聚焦创新药,这些个股被重仓
博时基金唐屹兵旗下博时上证科创板100ETF中报最新持仓,重仓百济神州
证券之星 · 07-20
博时基金唐屹兵旗下博时上证科创板100ETF中报最新持仓,重仓百济神州
百济神州(ONC)盘前涨近4% 机构料公司第二季收入按年升33%至12亿美元
金吾财讯 · 07-18
百济神州(ONC)盘前涨近4% 机构料公司第二季收入按年升33%至12亿美元
加载更多
公司概况
公司名称:
百济神州有限公司
所属行业:
医药制造业
上市日期:
2021-12-15
主营业务:
百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希(安维汀生物类似药)、百拓维(注射用戈舍瑞林微球)、泰菲乐(达拉非尼)、迈吉宁(曲美替尼)、维全特(帕唑帕尼)、飞尼妥(依维莫司)、赞可达(塞瑞替尼)。
发行价格:
192.60
{"stockData":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":242,"timestamp":1753858800000,"preClose":245.78,"halted":0,"volume":2243506,"delay":0,"changeRate":-0.0154,"floatShares":114999999,"shares":1540000000,"eps":-2.0553,"marketStatus":"已收盘","change":-3.78,"latestTime":"07-30 15:00:00","open":246,"high":249.69,"low":240.58,"amount":550000000,"amplitude":0.0371,"askPrice":242.1,"askSize":2,"bidPrice":242,"bidSize":11,"shortable":0,"etf":0,"ttmEps":-2.0553,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753925400000},"marketStatusCode":5,"adr":0,"adjPreClose":245.78,"symbolType":"stock_kcb","openAndCloseTimeList":[[1753839000000,1753846200000],[1753851600000,1753858800000]],"highLimit":270.36,"lowLimit":221.2,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1539858562,"isCdr":false,"pbRate":14.78,"roa":"--","roe":"--","epsLYR":-3.64,"committee":0.117647,"marketValue":372646000000,"turnoverRate":0.0195,"status":1,"afterMarket":{"amount":0,"volume":0,"close":242,"buyVolume":200,"sellVolume":0,"time":1753860838019,"indexStatus":"已收盘 07-30 15:30:00","preClose":245.78},"hkstockBrief":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":182.4,"timestamp":1753862890007,"preClose":185.9,"halted":0,"volume":8008868,"delay":0,"premium":"-30.95"},"floatMarketCap":27843000000},"requestUrl":"/m/hq/s/688235","defaultTab":"news","newsList":[{"id":"2555090072","title":"港股异动 | 百奥赛图-B(02315)涨超10% 与百济神州达成抗体分子全球许可协议 机构称上半年经营情况超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2555090072","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555090072?lang=zh_cn&edition=full","pubTime":"2025-07-30 14:48","pubTimestamp":1753858116,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B午后涨超10%,截至发稿,涨5.53%,报24.8港元,成交额2040.81万港元。消息面上,百奥赛图近期宣布,与全球肿瘤治疗创新公司百济神州达成抗体分子的全球许可协议。根据协议条款,百济神州将向百奥赛图支付首付款。东吴证券指出,百奥赛图上半年经营情况超预期,BD持续放量,包括与正大天晴合作的IGF1R抗体获批中国IND,并由百奥赛图主导海外BD。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1323549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4526","LU2328871848.SGD","LU0307460666.USD","BK1588","02315","BK1161","BK4139","BK1500","BK0239","BK4585","LU0588546209.SGD","06160","LU1969619763.USD","ONC","688235","BK1583"],"gpt_icon":0},{"id":"2555369099","title":"生物制品行业深度报告:多发性硬化 百亿美金市场 BTKI发展前景广阔","url":"https://stock-news.laohu8.com/highlight/detail?id=2555369099","media":"开源证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555369099?lang=zh_cn&edition=full","pubTime":"2025-07-30 00:00","pubTimestamp":1753804800,"startTime":"0","endTime":"0","summary":"MS 地理分布呈现鲜明的“纬度梯度”现象,高纬度地区发病率较高;根据Frost & Sullivan数据,全球与中国多发性硬化存量患者数量预计将在2030 年达到371/6 万人。BTK 抑制剂有望填补PMS 领域治疗空白,2025H2 数据催化密集BTK 抑制剂具有较好的血脑屏障穿透性,可通过调控B 细胞和小胶质细胞等关键免疫细胞,分别抑制炎症反应和神经退行性进程,为PMS 提供了潜在有效的治疗手段。投资建议MS 全球存量患者基数较大,存量产品市场规模约200 亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730111622a6c8dd18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730111622a6c8dd18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688428","LU1655091616.SGD","03692","LU2495084118.USD","603392","688488","BK0012","LU1997244956.HKD","688136","688336","LU2580892862.HKD","600161","LU1064131003.USD","LU2328871848.SGD","LU1064130708.USD","688276","LU2580892789.USD","688235","BK0239","LU2148510915.USD","01276","BK0188","688670","09969","688319","01952","688739","688105","BK0060","BK0196","BK0028","600276","LU0405327494.USD","600739","LU2488822045.USD","BK0183","LU1997245094.SGD","LU1969619763.USD","LU1328615791.USD","600211","LU0405327148.USD","688163","LU1997245177.USD"],"gpt_icon":0},{"id":"2555805287","title":"创新药,彻底疯了","url":"https://stock-news.laohu8.com/highlight/detail?id=2555805287","media":"北海茶客投研笔记","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555805287?lang=zh_cn&edition=full","pubTime":"2025-07-29 21:31","pubTimestamp":1753795861,"startTime":"0","endTime":"0","summary":"为什么茶客今年能成功预言创新药会形成抱团式的爆炒?三股抱团势力创新药的交易节奏和市值版图首先,从基本面来讲,创新药这个行业是真正在发生剧变的行业,是AH两市中为数不多真正有产业趋势的行业。这一点茶客之前讲过很多:中国创新药崛起之谜:从科学到工程学中国的创新药,到底发展到什么阶段了?毕竟在公募基金这种聪明人扎堆内卷的机构,如果这一次不能证明自己,就永远没有下一次机会了。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729214931a469ce08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729214931a469ce08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","01276","BK0239","06160","02197","06628","688235","600276","01228","01801","09926","159992"],"gpt_icon":0},{"id":"2555039011","title":"一线疗法!百济神州/安进在国内启动 DLL3/CD3 双抗新 III 期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2555039011","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555039011?lang=zh_cn&edition=full","pubTime":"2025-07-29 17:05","pubTimestamp":1753779943,"startTime":"0","endTime":"0","summary":"7 月 28 日,药物临床试验登记与信息公示平台显示,百济神州/安进登记了一项Tarlatamab用于未经治疗的广泛期小细胞肺癌患者的 III 期临床。塔拉妥单抗是一款由安进公司研发的创新靶向免疫疗法,能够同时结合肿瘤细胞上的 DLL3 蛋白和 T 细胞上的 CD3 蛋白,进而激活 T 细胞来杀伤表达 DLL3 蛋白的肿瘤细胞。其中,三线疗法已于日前在国内报上市并已进入优先审评通道。该研究旨在评估其用于 SCLC 二线治疗的疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729171949a4696069&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729171949a4696069&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AMGN","LU0109394709.USD","IE00B4R5TH58.HKD","BK4139","BK4533","BK4581","IE00B2B36J28.USD","BK4599","LU1983299246.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","III","LU2112291526.USD","BK4534","LU0289739699.SGD","LU1571399168.USD","06160","IE0009355771.USD","BK4585","LU1061106388.HKD","LU2242652126.USD","BK4566","LU1023059063.AUD","LU0889565916.HKD","BK4588","688235","LU0058720904.USD","IE00BJT1NW94.SGD","LU0122379950.USD","LU1057294990.SGD","LU2242646821.SGD","IE0002141913.USD","ONC","LU2089984988.USD","IE00BFTCPJ56.SGD","BK4526","LU0868494617.USD","LU2468319806.SGD","BK4134","SG9999001440.SGD"],"gpt_icon":0},{"id":"2555035386","title":"港股收评:午后回升!恒指小幅下跌0.15%,创新药涨幅抢眼,三胎概念股高开低走","url":"https://stock-news.laohu8.com/highlight/detail?id=2555035386","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555035386?lang=zh_cn&edition=full","pubTime":"2025-07-29 16:21","pubTimestamp":1753777290,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["02186","MIUmain","01093","601939","603259","688428","KSTmain","03086","HSImain","01801","BABA","01810","08496","TTTN","02359","688235","TCHmain","HHImain","06978","HTCD.SI","TCEHY","06160","MCHmain","09618","MHImain","HSCEI","09969","METmain","01024","HSI","ALBmain","01530","01288","00939","00700","601288","03690","161726","HSTECH","601398","MPNGY","BIDU","JD","399441","01398","YANG","ONC","159992","07226"],"gpt_icon":0},{"id":"2555038763","title":"基金二季报陆续披露,中欧葛兰等基金经理加码创新药板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2555038763","media":"全景网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555038763?lang=zh_cn&edition=full","pubTime":"2025-07-29 15:19","pubTimestamp":1753773595,"startTime":"0","endTime":"0","summary":"随着基金二季报陆续披露, 创新药 板块成为众多基金经理关注的焦点,葛兰、谢治宇、傅鹏博、高楠等基金经理也纷纷加码创新药板块。展望三季度,在创新药领域,中欧基金葛兰在二季报中表示,看好全球合作深化与重要临床数据披露预期。睿远基金傅鹏博在二季度增加了医药板块配置,涉及创新药等子行业;永赢基金高楠管理的永赢睿信,在将 康方生物 、百济神州- U买进重仓股后,还在继续加码创新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729152818a4691f68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729152818a4691f68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09926","ONC","BK4526","06160","BK4139","688235","01801"],"gpt_icon":0},{"id":"2555866160","title":"百济神州:百泽安获欧洲药品管理局人用药品委员会积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2555866160","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555866160?lang=zh_cn&edition=full","pubTime":"2025-07-29 10:45","pubTimestamp":1753757135,"startTime":"0","endTime":"0","summary":"7月29日,据$百济神州$官微消息,7月28日,公司宣布欧洲药品管理局人用药品委员会发布积极意见,推荐批准百泽安联合含铂化疗用于存在高复发风险的可切除非小细胞肺癌成人患者的术前新辅助治疗,并在术后继续使用替雷利珠单抗单药进行辅助治疗。","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322972.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百济神州:百泽安获欧洲药品管理局人用药品委员会积极意见","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK1500","BK4087","BK4526","LU1969619763.USD","LU2328871848.SGD","LU0588546209.SGD","BK0239","688235","BK1161","BK1583","LU0307460666.USD","ONC","BK4139","06160"],"gpt_icon":0},{"id":"2555704118","title":"国内稀缺、研发实力强!7家创新药企手握重磅新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2555704118","media":"巨丰投顾","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555704118?lang=zh_cn&edition=full","pubTime":"2025-07-29 05:59","pubTimestamp":1753739961,"startTime":"0","endTime":"0","summary":"核心龙头业绩高速增长提及恒瑞医药上涨10%。创新药作为医药生物板块的核心投资主线,近期在政策、市场等多方面迎来积极变化。受益于海外订单的持续增长以及国内创新药研发的提速,这些企业整体盈利能力和成长性得到提升,2025年上半年业绩表现超出市场预期。2025年上半年创新药收入占比超45%,半年报业绩预增,其HER2 ADC药物临床数据优于同类产品,有望成为重磅炸弹级产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729060051a46849a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729060051a46849a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK4526","688235","ONC","01276","BK4139","600276","688180","06160"],"gpt_icon":0},{"id":"2554476027","title":"港股异动 | 百奥赛图-B(02315)涨超3% 近日宣布与百济神州达成抗体分子全球许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2554476027","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554476027?lang=zh_cn&edition=full","pubTime":"2025-07-28 11:20","pubTimestamp":1753672815,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B涨超3%,截至发稿,涨2.64%,报21.35港元,成交额450.75万港元。消息面上,近日,据百奥赛图官微消息,公司宣布与全球肿瘤治疗创新公司百济神州达成抗体分子的全球许可协议。根据协议条款,百济神州将向百奥赛图支付首付款。据介绍,百济神州此前已获得百奥赛图RenMice全人抗体平台的授权使用许可,本次双方在已建立的良好合作基础上进一步将合作拓展至抗体分子授权许可领域,标志着双方合作的持续深化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0307460666.USD","BK1588","BK4139","LU2328871848.SGD","LU0588546209.SGD","02315","BK0239","ONC","LU1969619763.USD","BK1500","BK1583","688235","BK4526","BK1161","06160"],"gpt_icon":0},{"id":"2554734415","title":"单抗概念盘中拉升,誉衡药业涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2554734415","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554734415?lang=zh_cn&edition=full","pubTime":"2025-07-25 09:37","pubTimestamp":1753407453,"startTime":"0","endTime":"0","summary":"07月25日,单抗概念盘中拉升,截至09点37分,单抗概念整体指数上涨0.66%,报2690.320点。从个股上来看,该概念的成分股中,誉衡药业涨停,百济神州-U、华海药业、华东医药涨幅居前。从资金上来看,截止发稿,单抗概念概念主力净流入为-4863.45万,其中誉衡药业受到资金热捧,主力净流入1.18亿;拉长时间线来看,该板块近20日主力资金净流入-4.73亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725093733971d2e99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725093733971d2e99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0201","BK0012","BK0185","688235","BK0070","BK0095","002437","BK0060","BK0077","BK0028","BK0188","BK0239","600521"],"gpt_icon":0},{"id":"2554877817","title":"百济神州-U股价微跌0.19% 二季度获201家基金重仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2554877817","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554877817?lang=zh_cn&edition=full","pubTime":"2025-07-25 02:33","pubTimestamp":1753382029,"startTime":"0","endTime":"0","summary":"截至2025年7月24日收盘,百济神州-U股价报237.68元,较前一交易日下跌0.45元,跌幅0.19%。当日成交量为21877手,成交金额达5.20亿元。百济神州-U属于医药生物行业,是一家专注于创新药物研发的生物科技企业。公司主要从事肿瘤、免疫肿瘤等领域的创新药物研发、生产和商业化。数据显示,2025年二季度末共有201家基金重仓持有百济神州-U,合计持股3850.52万股,占流通股比例达33.47%。在科创板公司中,百济神州-U的基金持股比例排名第二。7月24日,百济神州-U主力资金净流出453.23万元,占流通市值比例为0.02%。风险提示:投资有风险,入市需谨慎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725023955971c9964&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725023955971c9964&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","BK0239","06160"],"gpt_icon":0},{"id":"2553078322","title":"新事丨罗氏终止TIGIT全部三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2553078322","media":"健识局","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553078322?lang=zh_cn&edition=full","pubTime":"2025-07-24 20:30","pubTimestamp":1753360205,"startTime":"0","endTime":"0","summary":"在最新的管线中,PD-1联合TIGIT治疗非小细胞肺癌、肝癌的三期临床均已终止。这意味着罗氏针对TIGIT进行的三期临床全部终止。TIGIT靶点的价值是罗氏在2009年最先发现的。当时,罗氏的TIGIT+PD-L1联合疗法的效果曾一鸣惊人,一度被认为是PD-1之后的免疫新星。全球范围内,这几年TIGIT单抗预期快速变化:默沙东、罗氏等药企都已经历多次失败,留给TIGIT靶点成功的希望相当渺茫。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724203245a6bfb977&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724203245a6bfb977&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MRK","BK0012","01276","LU0405327494.USD","BK0196","LU1997245094.SGD","LU2148510915.USD","LU0405327148.USD","01801","LU1969619763.USD","LU2495084118.USD","LU1064131003.USD","BK0239","688266","LU1997244956.HKD","BK0183","LU1328615791.USD","688235","LU1064130708.USD","688177","06160","LU2488822045.USD","600276","BK0028","LU1655091616.SGD","LU1997245177.USD","LU2328871848.SGD","BK0188","ONC","BK0060"],"gpt_icon":1},{"id":"2553216134","title":"百济潜在 BIC 蛋白降解剂获批新临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2553216134","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553216134?lang=zh_cn&edition=full","pubTime":"2025-07-23 16:28","pubTimestamp":1753259310,"startTime":"0","endTime":"0","summary":"7 月 23 日,CDE 官网显示,百济神州BGB-45035 片获批临床,用于治疗类风湿性关节炎。这是继特应性皮炎和结节性痒疹后,BGB-45035 获批的第三项临床。来源:CDE 官网BGB-45035 是一款靶向白细胞介素 1 受体相关激酶4的 蛋白降解剂。据百济介绍,BGB-45035 具有同类最佳潜力,在临床前模型中,相比 KT474,BGB-45035 可带来更快、更深度的 IRAK4 降解,且细胞因子抑制作用更强。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723173827a6bd0654&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723173827a6bd0654&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC","BK0239","688235"],"gpt_icon":0},{"id":"2553226751","title":"单抗概念盘中拉升,百济神州-U涨0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553226751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553226751?lang=zh_cn&edition=full","pubTime":"2025-07-23 09:39","pubTimestamp":1753234793,"startTime":"0","endTime":"0","summary":"07月23日,单抗概念盘中拉升,截至09点39分,单抗概念整体指数上涨0.66%,报2657.650点。从个股上来看,该概念的成分股中,百济神州-U涨0.48%,上海医药、国药一致、华海药业涨幅居前。从资金上来看,截止发稿,单抗概念概念主力净流入为-1.40亿,其中苑东生物受到资金热捧,主力净流入348.54万;拉长时间线来看,该板块近20日主力资金净流入5384.79万。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723093953954dd1c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723093953954dd1c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","BK0201","BK0185","688235","BK0188","BK0028","BK0070","BK0239","600521","688513"],"gpt_icon":0},{"id":"2553575942","title":"券商资管系公募,排名来了!","url":"https://stock-news.laohu8.com/highlight/detail?id=2553575942","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553575942?lang=zh_cn&edition=full","pubTime":"2025-07-23 00:06","pubTimestamp":1753200372,"startTime":"0","endTime":"0","summary":"头部券商资管公募管理规模普遍增长Wind数据显示,截至二季度末,共有4家券商资管机构的公募基金资产管理总规模超千亿元。此外,相比于今年一季度末,头部券商资管的公募管理规模普遍增长,东方红资产管理、华泰证券资管规模增长均超200亿元,招商证券资管规模增长33亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723001401a45cdc20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723001401a45cdc20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","688428","BK0239","06160","01276","ONC","688192","688235","688443","688266","600276","09969"],"gpt_icon":0},{"id":"2553207288","title":"百济神州盘中异动 早盘快速上涨3.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553207288","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553207288?lang=zh_cn&edition=full","pubTime":"2025-07-22 09:44","pubTimestamp":1753148680,"startTime":"0","endTime":"0","summary":"2025年07月22日早盘09时44分,百济神州股票出现异动,股价急速拉升3.02%。截至发稿,该股报180.900港元/股,成交量74.7922万股,换手率0.05%,振幅3.25%。机构评级方面,在所有32家参与评级的机构中,97%的券商给予买入建议,3%的券商给予持有建议,无券商给予卖出建议。百济神州股票所在的生物技术行业中,整体涨幅为0.06%。百济神州公司简介:百济神州是一家全球性、商业阶段的生物科技公司,专注于研究、开发、生产以及商业化创新型药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722094440a6b96e65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722094440a6b96e65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239","06160"],"gpt_icon":0},{"id":"2553008144","title":"公募基金2025年二季报全扫描【国信金工】","url":"https://stock-news.laohu8.com/highlight/detail?id=2553008144","media":"量化藏经阁","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553008144?lang=zh_cn&edition=full","pubTime":"2025-07-22 08:06","pubTimestamp":1753142805,"startTime":"0","endTime":"0","summary":"一基金仓位监控在跟踪基金仓位变化时,由于2015年四季度以前股票型基金仓位规定下限为60%,在这之后规定为80%。截至2025年二季报,科技类板块配置权重依旧最高,最新一期配置权重为37.42%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722082610a6b94be8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722082610a6b94be8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BYDDY","09988","BK4588","YANG","600519","09969","ONC","BK4099","03750","BK4585","688428","688235","BK4614","EVS.SI"],"gpt_icon":0},{"id":"2553842793","title":"葛兰、谢治宇最新持仓曝光:共同聚焦创新药,这些个股被重仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2553842793","media":"每经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553842793?lang=zh_cn&edition=full","pubTime":"2025-07-21 16:56","pubTimestamp":1753088193,"startTime":"0","endTime":"0","summary":"另外,兴证全球基金谢治宇管理的兴全合润,二季度减持了比亚迪、海尔智家,转而重仓分众传媒、蓝思科技。葛兰二季度加码创新药先从中欧医疗健康来看,二季度虽然出现净赎回的情况,但整体份额依然超过185亿份,规模超过300亿元。整体来看,创新药行业的持仓个股数量进一步增加,而多只医疗个股、中药个股已不见身影。可以看出,谢治宇二季度也偏爱创新药,重仓了多只个股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721165943a459004f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721165943a459004f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BYDDY","BK0188","01530","03347","BK0028","688428","600160","01415","BK0196","159992","688235","01211","03750","BK0044","81211","06690","BK0229","09969","06613","600690","01801","BK0015","688099","03759"],"gpt_icon":0},{"id":"2553146441","title":"博时基金唐屹兵旗下博时上证科创板100ETF中报最新持仓,重仓百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2553146441","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553146441?lang=zh_cn&edition=full","pubTime":"2025-07-21 07:10","pubTimestamp":1753053035,"startTime":"0","endTime":"0","summary":"证券之星消息,7月21日博时基金旗下唐屹兵管理的博时上证科创板100交易型开放式指数基金公布中报,近1年净值增长率45.36%。与上一季度相比,该基金前十大重仓股新增华虹公司,中科飞测,安集科技,纳芯微;其中百济神州持仓占比3.01%,为该基金第一大重仓股;恒玄科技,绿的谐波,乐鑫科技,铂力特等退出前十大重仓股;详细数据如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072100001574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159982","LU0307460666.USD","688235","LU0588546209.SGD","000001.SH","BK1500","BK1588","LU2328871848.SGD","399300","588120","BK1161","BK1583","06160","BK0239","LU1969619763.USD"],"gpt_icon":0},{"id":"2552626304","title":"百济神州(ONC)盘前涨近4% 机构料公司第二季收入按年升33%至12亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552626304","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552626304?lang=zh_cn&edition=full","pubTime":"2025-07-18 19:26","pubTimestamp":1752837999,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州(ONC)盘前涨近4%,截至发稿,报301.260美元 。 消息面上,野村发表报告,料百济神州第二季收入按年升33%至12亿美元,与市场预期一致。该行预测百悦泽维持市场领导地位,次季销售按年升39%至8.84亿美元,其中美欧销售分别按年升35%及80%,至6.47亿及1.4亿美元。百泽安内地市场销售料按年升15%至1.82亿美元。此外,摩根大通分析师Jessica Fye维持百济神州买入评级,并将目标价从321美元上调至345美元。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"290592","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","BK1161","BK1588","LU2328871848.SGD","LU0307460666.USD","BK4526","LU0588546209.SGD","BK1500","BK4139","688235","BK0239","BK1583","LU1969619763.USD","06160"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753878156567,"stockEarnings":[{"period":"1week","weight":0.0383},{"period":"1month","weight":0.041},{"period":"3month","weight":-0.059},{"period":"6month","weight":0.2889},{"period":"1year","weight":0.9775},{"period":"ytd","weight":0.5264}],"compareEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":0.0542},{"period":"3month","weight":0.1008},{"period":"6month","weight":0.1105},{"period":"1year","weight":0.2482},{"period":"ytd","weight":0.077}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百济神州有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"24071人(较上一季度减少23.72%)","perCapita":"4779股","listingDate":"2021-12-15","address":"c/oBeOneMedicinesIGmbH,Aeschengraben27,4051Basel,Switzerland","registeredCapital":"15万元","survey":" 百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希(安维汀生物类似药)、百拓维(注射用戈舍瑞林微球)、泰菲乐(达拉非尼)、迈吉宁(曲美替尼)、维全特(帕唑帕尼)、飞尼妥(依维莫司)、赞可达(塞瑞替尼)。","listedPrice":192.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,688235,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}